Vidal J, Morínigo R, Codoceo V H, Casamitjana R, Pellitero S, Gomis R
Obesity unit, Hospital Clínic Universitari, Barcelona, Spain.
Int J Obes (Lond). 2005 Jun;29(6):668-74. doi: 10.1038/sj.ijo.0802921.
To investigate whether the association between the metabolic syndrome (MS) and cardiovascular disease (CVD) in obese adults is influenced by the criteria used to diagnose the MS.
Cross-sectional study in 389 obese adults (male/female: 26%/74%; body mass index (BMI): 30.1-63.2 kg/m2; age: 18-79 y).
To diagnose the MS by the WHO or the ATPIII criteria, body mass index, waist circumference, fasting and 2-h oral Glucose tolerance test plasma glucose, fasting plasma triglycerides and HDL cholesterol, systolic and diastolic blood pressure, 24-h albumin excretion, and fasting insulin were measured. The association between the MS diagnosed with either definition and self-referred CVD was investigated.
The prevalence of the MS by the WHO was higher than by the ATPIII criteria (WHO 69.1%, ATPIII 49.4%; P<0.001). The MS diagnosed by the WHO criteria was significantly associated with self-referred CVD (odds ratio (OR) 5.80, 95% CI 1.35-24.95, P<0.05), whereas the ATPIIII MS was not (OR 1.34, 95% CI 0.59-3.03). An elevated blood pressure (OR 5.04, 95% CI 1.41-18.01, P<0.05) and microalbuminuria (OR 2.61, 95% CI 1.06-6.40, P<0.05) were independently associated with CVD. Consideration of the OGTT data as part of the ATPIII MS definition improved its associations with CVD (OR 4.39, 95% CI 1.29-14.94, P<0.05).
The WHO criteria appear to identify a greater number of obese adults at risk for CVD. Nevertheless, the addition of an OGTT at least in nondiabetic patients with two ATPIII-defined metabolic risk factors may help to improve the association between the MS and CVD in obese adults.
研究肥胖成年人中代谢综合征(MS)与心血管疾病(CVD)之间的关联是否受用于诊断MS的标准影响。
对389名肥胖成年人进行横断面研究(男性/女性:26%/74%;体重指数(BMI):30.1 - 63.2 kg/m²;年龄:18 - 79岁)。
采用世界卫生组织(WHO)或美国国家胆固醇教育计划成人治疗组第三次报告(ATPIII)标准诊断MS,测量体重指数、腰围、空腹及口服葡萄糖耐量试验2小时血浆葡萄糖、空腹血浆甘油三酯和高密度脂蛋白胆固醇、收缩压和舒张压、24小时尿白蛋白排泄量以及空腹胰岛素。研究两种定义诊断的MS与自述CVD之间的关联。
根据WHO标准诊断的MS患病率高于ATPIII标准(WHO为69.1%,ATPIII为49.4%;P<0.001)。根据WHO标准诊断的MS与自述CVD显著相关(比值比(OR)5.80,95%置信区间1.35 - 24.95,P<0.05),而ATPIII定义的MS则不然(OR 1.34,95%置信区间0.59 - 3.03)。血压升高(OR 5.04,95%置信区间1.41 - 18.01,P<0.05)和微量白蛋白尿(OR 2.61,95%置信区间1.06 - 6.40,P<0.05)与CVD独立相关。将口服葡萄糖耐量试验(OGTT)数据纳入ATPIII MS定义可改善其与CVD的关联(OR 4.39,95%置信区间1.29 - 14.94,P<0.05)。
WHO标准似乎能识别出更多有CVD风险的肥胖成年人。然而,至少在有两个ATPIII定义的代谢危险因素的非糖尿病患者中增加OGTT检查可能有助于改善肥胖成年人中MS与CVD之间的关联。